FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.6  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Dasatinib 63.2mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 800micrograms/0.2ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Bevacizumab 5mg/0.2ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Dasatinib 39.5mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 126mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 378mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 42mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 105mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 147mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 63mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 46.2mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 336mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 441mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 210mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 176.4mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 88.2mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 75.6mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 54.6mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 252mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 294mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 1029mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 735mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 651mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 504mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 1323mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 1176mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 588mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 882mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 70mg/100ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 60mg/100ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 50mg/100ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 165mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Melphalan 200mg powder and solvent for solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 150mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 315mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 90mg/250ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 200mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 100mg/250ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 120mg/250ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 55mg/100ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 180mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 350mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 135mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 395mg/1000ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 75mg/250ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 80mg/250ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 110mg/250ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 65mg/100ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Sunitinib 37.5mg capsules Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Imatinib 600mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cabazitaxel 60mg/3ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Imatinib 80mg/ml oral solution sugar free Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Thiotepa 400mg powder and 400ml solvent infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Peginterferon beta-1a 125micrograms/0.5ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Amsacrine 75mg/1.5ml concentrate and solvent for solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ruxolitinib 5mg tablets Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cyclophosphamide 100mg/5ml oral solution Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 20mg/2ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cyclophosphamide 1260mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pemetrexed 1g/40ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 40mg/1.6ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pemetrexed 100mg/4ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Gemcitabine 1.4g/140ml infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pegaspargase 3,750units/5ml solution for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Peginterferon alfa-2a 180micrograms/0.5ml solution for injection pre-filled disposable devices Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Megestrol 50mg capsules Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Olaparib 50mg capsules Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Mercaptopurine 100mg/5ml oral suspension Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Oxaliplatin 280mg/500ml in Glucose 5% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Docetaxel 132mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ipilimumab 50mg/10ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 50mg/2ml solution for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cladribine 10mg/10ml solution for infusion vials Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Triptorelin 11.25mg powder and solvent for suspension for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Docetaxel 20mg/0.5ml solution for injection vials and diluent Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cytarabine 100mg/1ml solution for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 45mg/1.8ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Imatinib 100mg tablets Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pazopanib 200mg tablets Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Aflibercept 200mg/8ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 15mg/0.6ml solution for injection pre-filled disposable devices Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Epirubicin 100mg/50ml solution for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Mitomycin 40mg powder and solvent for intravesical solution vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 25mg/1ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Bendamustine 180mg/4ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 5g/50ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 17.5mg/5ml oral suspension Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Fluorouracil 2800mg/105ml in Sodium chloride 0.9% infusion elastomeric devices Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab 600mg/5ml solution for injection vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Idelalisib 150mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cisplatin 33mg/250ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Gemcitabine 200mg/5.26ml solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 30mg/0.6ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Methotrexate 27.5mg/0.55ml solution for injection pre-filled disposable devices Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Thiotepa 100mg powder for solution for infusion vials Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Vincristine 1mg/50ml in Sodium chloride 0.9% infusion bags Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Fluorouracil 1350mg/105ml in Sodium chloride 0.9% infusion elastomeric devices Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Interferon beta-1a 6million units/0.5ml solution for injection pre-filled syringes and Interferon beta-1a 2.4million units/0.2ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Fluorouracil 3150mg/300ml in Sodium chloride 0.9% infusion elastomeric devices Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Rucaparib 300mg tablets Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Peginterferon alfa-2a 180micrograms/0.5ml solution for injection pre-filled syringes Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 17 of 26 Next End

This concept is not in any reference sets

Back to Start